People with type 2 diabetes who are treated with newer insulin analogs don’t have better outcomes than those who take human insulin, which is significantly less costly. That’s according to a study conducted by researchers at Kaiser Permanente and the Yale School of Medicine, and published in the JAMA.
This real-world study involved a large, diverse group of people with type 2 diabetes who had recently been prescribed insulin. In clinical trials, insulin analogs slightly lowered the risk of having low blood sugar levels at night – called nocturnal hypoglycemia – compared to human insulin. But the Yale and Kaiser researchers found that the analogs didn’t control blood sugar better or significantly lessen episodes of hypoglycemia requiring emergency medical care during the study period of about 18 months.
Both human insulin and long-acting insulin analogs are usually prescribed as daily or twice-daily injections to control blood sugar. The difference in cost is significant – insulin analogs can cost as much as 10 times more than human insulin.
Sourced from: JAMA